CLINICAL TRIALS PROFILE FOR ONIVYDE
✉ Email this page to a colleague
All Clinical Trials for ONIVYDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02231723 ↗ | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer | Completed | Boston Biomedical, Inc | Phase 1 | 2014-08-01 | This is an open label, multi-center, multi-arm, dose-escalation study of BBI608 administered in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or MM-398 with 5-FU and leucovorin. |
| NCT02231723 ↗ | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer | Completed | Sumitomo Dainippon Pharma Oncology, Inc | Phase 1 | 2014-08-01 | This is an open label, multi-center, multi-arm, dose-escalation study of BBI608 administered in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or MM-398 with 5-FU and leucovorin. |
| NCT02631733 ↗ | Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors | Active, not recruiting | National Cancer Institute (NCI) | Phase 1 | 2016-07-15 | This phase I trial studies the side effects and best dose of veliparib when given together with liposomal irinotecan in treating patients with solid tumors. Liposomal irinotecan and veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
| NCT02785068 ↗ | Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer | Withdrawn | Merrimack Pharmaceuticals | Phase 1/Phase 2 | 2016-07-01 | A phase 1b/2a study evaluating the combination of MM-151 + nal-IRI + 5-FU + Leucovorin in RAS/RAF wild-type Metastatic Colorectal Cancer. |
| NCT02826486 ↗ | Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) | Active, not recruiting | Merck Sharp & Dohme Corp. | Phase 2 | 2016-09-01 | This study will assess the efficacy and safety of BL-8040 in combination with pembrolizumab (Keytruda®) and BL8040/ Pembrolizumab in combination with liposomal irinotecan (Onivyde®)/5-fluorouracil/leucovorin (5-FU/LV) in subjects with metastatic pancreatic adenocarcinoma. |
| NCT02826486 ↗ | Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) | Active, not recruiting | BioLineRx, Ltd. | Phase 2 | 2016-09-01 | This study will assess the efficacy and safety of BL-8040 in combination with pembrolizumab (Keytruda®) and BL8040/ Pembrolizumab in combination with liposomal irinotecan (Onivyde®)/5-fluorouracil/leucovorin (5-FU/LV) in subjects with metastatic pancreatic adenocarcinoma. |
| NCT03088813 ↗ | Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer | Active, not recruiting | Ipsen | Phase 2/Phase 3 | 2018-04-25 | A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy The study will be conducted in two parts: 1. Dose determination of irinotecan liposome injection 2. A randomized, efficacy study of irinotecan liposome injection versus topotecan |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ONIVYDE
Condition Name
Clinical Trial Locations for ONIVYDE
Trials by Country
Clinical Trial Progress for ONIVYDE
Clinical Trial Phase
Clinical Trial Sponsors for ONIVYDE
Sponsor Name
